A5003873298- Multiple Sclerosis Research Studies
- Polyomavirus and related diseases
- Sphingolipid Metabolism and Signaling
- SARS-CoV-2 and COVID-19 Research
- Peripheral Neuropathies and Disorders
- Acute Lymphoblastic Leukemia research
- Systemic Lupus Erythematosus Research
- Long-Term Effects of COVID-19
- Brucella: diagnosis, epidemiology, treatment
- Atrial Fibrillation Management and Outcomes
- COVID-19 Clinical Research Studies
- Infectious Diseases and Mycology
- Inflammasome and immune disorders
- Systemic Sclerosis and Related Diseases
- Multiple Myeloma Research and Treatments
- Autoimmune and Inflammatory Disorders Research
- Viral Infections and Immunology Research
- Liver Diseases and Immunity
- Biotechnology and Related Fields
- Burkholderia infections and melioidosis
- Sarcoidosis and Beryllium Toxicity Research
- Leptospirosis research and findings
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Neuroinflammation and Neurodegeneration Mechanisms
Inserm
2023-2024
Lebanese American University
2011-2024
Université de Limoges
2024
Institut de Recherche pour le Développement
2023-2024
Middle East University
2024
Rafik Hariri University Hospital
2023
Institut d’Epidémiologie Neurologique et de Neurologie Tropicale
2022-2023
Harley-Davidson (United States)
2023
American University of Beirut Medical Center
2015-2022
Institut d’Epidémiologie et de Neurologie Tropicale
2022
Objective . To evaluate the efficacy and safety of rituximab in multiple sclerosis a clinical practice setting. Methods Clinical data for all adult patients with (MS) treated off-label at single MS center Lebanon between March 2008 April 2017 were retrospectively collected from medical charts. The main outcomes assessed annualized relapse rate (ARR) proportion free relapses, disability progression, or magnetic resonance imaging (MRI) activity. Results A total 89 rituximab-treated included:...
We report two cases of neuromyelitis optica spectrum disorder (NMOSD) who were misdiagnosed as multiple sclerosis (MS) and developed catastrophic relapses following initiation dimethyl fumarate. Both patients a severe myelitis extending from the cervical cord to medulla with significant swelling, resulting in complete quadriplegia respiratory difficulties, addition bilateral visual loss one patient. It is note that both occurred 2 3 months
Multiple sclerosis was long considered a relatively rare entity in the Middle East, but research over past 10 years and publication of East North Africa Committee for Treatment Research Sclerosis guidelines multiple have allowed diagnosis treatment to occur more efficiently. Most first second-line disease-modifying therapies approved by Food Drug Administration European Medicine Agency are available East. However, availability is quite variable, with some countries having access all...
Fingolimod is a daily oral medication used to treat relapsing multiple sclerosis (MS). Clinicians often adopt less frequent dosing for patients with profound drug-induced lymphopenia or other adverse events. Data on the effectiveness of alternate dose fingolimod are limited.We conducted multicenter, retrospective, observational study at 14 sites and identified 170 MS taking doses ≥1 month. Clinical radiologic outcomes were collected compared during dosing.Profound (77%), liver function...
The Lebanese American University (LAU) offers first-year pharmacy students with Introductory Pharmacy Practice Experience (IPPE) courses comprising various activities that provide direct patient contact so they can be geared up for "real-world" practice. Routine assessment and improvement in these are imperative to ensure efficiency of courses. This study was conducted evaluate the quality our IPPEs courses, determine its impact on student learning satisfaction, identify shortcomings program...
COVID-19 has been associated with a variety of multi-organs complications, an increasing proportion patients presenting neurologic manifestations. There is still uncertainty in the relationship between stroke and COVID-19. Therefore, this study, authors report 18 cases acute occurring setting infection, including 11 ischaemic strokes 7 haemorrhagic identified Lebanese tertiary hospital. In case series, had elevated markers inflammation coagulation. Ischaemic were treated different regimens...
One strategy to mitigate progressive multifocal leukoencephalopathy (PML) risk is switch other highly effective disease-modifying therapies (DMTs). However, the optimal DMT following natalizumab (NTZ) discontinuation yet be determined.